The Amgen story
What drives Amgen, what its price assumes and what could change the story, written from its own filings.
- Growth is changing hands. In the quarter to June 2026, Repatha sales grew 37% to $953 million while Prolia sales fell 32% to $759 million as biosimilar competition intensified.
- Cash improved unevenly. Free cash flow reached $3.5 billion in the quarter to June 2026, helped by business performance and the absence of the prior year’s final repatriation tax payment.
- Obesity requires spending. MariTide’s expanding Phase 3 program helped drive higher research spending in the quarter to June 2026, before its commercial potential has been established.
